Loading…
Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK
SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cell...
Saved in:
Published in: | Biochemical pharmacology 2013-09, Vol.86 (5), p.597-611 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3 |
container_end_page | 611 |
container_issue | 5 |
container_start_page | 597 |
container_title | Biochemical pharmacology |
container_volume | 86 |
creator | Huang, Rong Oh, Hyunju Arrendale, Allison Martin, Victoria A. Galan, Jacob Workman, Eric J. Stout, Jane R. Walczak, Claire E. Tao, W. Andy Borch, Richard F. Geahlen, Robert L. |
description | SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target. |
doi_str_mv | 10.1016/j.bcp.2013.06.024 |
format | article |
fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3755495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295213004115</els_id><sourcerecordid>S0006295213004115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3</originalsourceid><addsrcrecordid>eNp9kc1q3DAUhUVoSSZJHyCbRA-QcfVjaWwKhTA0bWhKF2l2BSFLVzOa2JaRNIG8fWWmDe2mC6G_7xzpnovQBSUVJVS-31WdmSpGKK-IrAirj9CCNiu-ZK1s3qAFIUSWtWAn6DSl3bxtJD1GJ4w3nDSMLdDPuzFHbaDv972OOOu4gZywCxFrPG1DKiO_xJD8CHiCKXsbBj9A9gb70fR7CzhvAQ8-h_nsqXCFvcbf1jdfz9Fbp_sE737PZ-jx9tOP9Zfl_ffPd-ub-6WpVyIvzco5yY11zIKlEiyw2gmmSWdqQV3LpSSM1RQ63hVBy6gwwraNMDWXLTX8DH08-E77bgBrYK6pV1P0g44vKmiv_r0Z_VZtwrPiKyHqVhQDejAwpdIUwb1qKVFz1GqnStRqjloRqUrURXP596Ovij_ZFuDqADgdlN5En9TjQ3EQpQ-Ml1YU4sOBgBLOs4eokvEwGrA-gsnKBv-fD_wCXtia2w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK</title><source>ScienceDirect Freedom Collection</source><creator>Huang, Rong ; Oh, Hyunju ; Arrendale, Allison ; Martin, Victoria A. ; Galan, Jacob ; Workman, Eric J. ; Stout, Jane R. ; Walczak, Claire E. ; Tao, W. Andy ; Borch, Richard F. ; Geahlen, Robert L.</creator><creatorcontrib>Huang, Rong ; Oh, Hyunju ; Arrendale, Allison ; Martin, Victoria A. ; Galan, Jacob ; Workman, Eric J. ; Stout, Jane R. ; Walczak, Claire E. ; Tao, W. Andy ; Borch, Richard F. ; Geahlen, Robert L.</creatorcontrib><description>SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2013.06.024</identifier><identifier>PMID: 23830822</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>adenosinetriphosphatase ; Cell Cycle ; Cell Line, Tumor ; chromosomes ; Drug delivery ; drugs ; endopolyploidy ; Humans ; Kinesin ; Kinesin - metabolism ; leukemia ; Ligands ; lymphoma ; MCAK ; mitotic spindle apparatus ; Peptidomimetic ; Peptidomimetics - metabolism ; Phosphorylation ; Phosphotyrosine - metabolism ; Protein Binding ; protein-protein interactions ; proteomics ; SH2 domain ; Signal transduction ; Spectrometry, Mass, Electrospray Ionization</subject><ispartof>Biochemical pharmacology, 2013-09, Vol.86 (5), p.597-611</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>2013 Elsevier Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3</citedby><cites>FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23830822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Rong</creatorcontrib><creatorcontrib>Oh, Hyunju</creatorcontrib><creatorcontrib>Arrendale, Allison</creatorcontrib><creatorcontrib>Martin, Victoria A.</creatorcontrib><creatorcontrib>Galan, Jacob</creatorcontrib><creatorcontrib>Workman, Eric J.</creatorcontrib><creatorcontrib>Stout, Jane R.</creatorcontrib><creatorcontrib>Walczak, Claire E.</creatorcontrib><creatorcontrib>Tao, W. Andy</creatorcontrib><creatorcontrib>Borch, Richard F.</creatorcontrib><creatorcontrib>Geahlen, Robert L.</creatorcontrib><title>Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.</description><subject>adenosinetriphosphatase</subject><subject>Cell Cycle</subject><subject>Cell Line, Tumor</subject><subject>chromosomes</subject><subject>Drug delivery</subject><subject>drugs</subject><subject>endopolyploidy</subject><subject>Humans</subject><subject>Kinesin</subject><subject>Kinesin - metabolism</subject><subject>leukemia</subject><subject>Ligands</subject><subject>lymphoma</subject><subject>MCAK</subject><subject>mitotic spindle apparatus</subject><subject>Peptidomimetic</subject><subject>Peptidomimetics - metabolism</subject><subject>Phosphorylation</subject><subject>Phosphotyrosine - metabolism</subject><subject>Protein Binding</subject><subject>protein-protein interactions</subject><subject>proteomics</subject><subject>SH2 domain</subject><subject>Signal transduction</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kc1q3DAUhUVoSSZJHyCbRA-QcfVjaWwKhTA0bWhKF2l2BSFLVzOa2JaRNIG8fWWmDe2mC6G_7xzpnovQBSUVJVS-31WdmSpGKK-IrAirj9CCNiu-ZK1s3qAFIUSWtWAn6DSl3bxtJD1GJ4w3nDSMLdDPuzFHbaDv972OOOu4gZywCxFrPG1DKiO_xJD8CHiCKXsbBj9A9gb70fR7CzhvAQ8-h_nsqXCFvcbf1jdfz9Fbp_sE737PZ-jx9tOP9Zfl_ffPd-ub-6WpVyIvzco5yY11zIKlEiyw2gmmSWdqQV3LpSSM1RQ63hVBy6gwwraNMDWXLTX8DH08-E77bgBrYK6pV1P0g44vKmiv_r0Z_VZtwrPiKyHqVhQDejAwpdIUwb1qKVFz1GqnStRqjloRqUrURXP596Ovij_ZFuDqADgdlN5En9TjQ3EQpQ-Ml1YU4sOBgBLOs4eokvEwGrA-gsnKBv-fD_wCXtia2w</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Huang, Rong</creator><creator>Oh, Hyunju</creator><creator>Arrendale, Allison</creator><creator>Martin, Victoria A.</creator><creator>Galan, Jacob</creator><creator>Workman, Eric J.</creator><creator>Stout, Jane R.</creator><creator>Walczak, Claire E.</creator><creator>Tao, W. Andy</creator><creator>Borch, Richard F.</creator><creator>Geahlen, Robert L.</creator><general>Elsevier Inc</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130901</creationdate><title>Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK</title><author>Huang, Rong ; Oh, Hyunju ; Arrendale, Allison ; Martin, Victoria A. ; Galan, Jacob ; Workman, Eric J. ; Stout, Jane R. ; Walczak, Claire E. ; Tao, W. Andy ; Borch, Richard F. ; Geahlen, Robert L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>adenosinetriphosphatase</topic><topic>Cell Cycle</topic><topic>Cell Line, Tumor</topic><topic>chromosomes</topic><topic>Drug delivery</topic><topic>drugs</topic><topic>endopolyploidy</topic><topic>Humans</topic><topic>Kinesin</topic><topic>Kinesin - metabolism</topic><topic>leukemia</topic><topic>Ligands</topic><topic>lymphoma</topic><topic>MCAK</topic><topic>mitotic spindle apparatus</topic><topic>Peptidomimetic</topic><topic>Peptidomimetics - metabolism</topic><topic>Phosphorylation</topic><topic>Phosphotyrosine - metabolism</topic><topic>Protein Binding</topic><topic>protein-protein interactions</topic><topic>proteomics</topic><topic>SH2 domain</topic><topic>Signal transduction</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Rong</creatorcontrib><creatorcontrib>Oh, Hyunju</creatorcontrib><creatorcontrib>Arrendale, Allison</creatorcontrib><creatorcontrib>Martin, Victoria A.</creatorcontrib><creatorcontrib>Galan, Jacob</creatorcontrib><creatorcontrib>Workman, Eric J.</creatorcontrib><creatorcontrib>Stout, Jane R.</creatorcontrib><creatorcontrib>Walczak, Claire E.</creatorcontrib><creatorcontrib>Tao, W. Andy</creatorcontrib><creatorcontrib>Borch, Richard F.</creatorcontrib><creatorcontrib>Geahlen, Robert L.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Rong</au><au>Oh, Hyunju</au><au>Arrendale, Allison</au><au>Martin, Victoria A.</au><au>Galan, Jacob</au><au>Workman, Eric J.</au><au>Stout, Jane R.</au><au>Walczak, Claire E.</au><au>Tao, W. Andy</au><au>Borch, Richard F.</au><au>Geahlen, Robert L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>86</volume><issue>5</issue><spage>597</spage><epage>611</epage><pages>597-611</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><abstract>SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>23830822</pmid><doi>10.1016/j.bcp.2013.06.024</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 2013-09, Vol.86 (5), p.597-611 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3755495 |
source | ScienceDirect Freedom Collection |
subjects | adenosinetriphosphatase Cell Cycle Cell Line, Tumor chromosomes Drug delivery drugs endopolyploidy Humans Kinesin Kinesin - metabolism leukemia Ligands lymphoma MCAK mitotic spindle apparatus Peptidomimetic Peptidomimetics - metabolism Phosphorylation Phosphotyrosine - metabolism Protein Binding protein-protein interactions proteomics SH2 domain Signal transduction Spectrometry, Mass, Electrospray Ionization |
title | Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T15%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intracellular%20targets%20for%20a%20phosphotyrosine%20peptidomimetic%20include%20the%20mitotic%20kinesin,%20MCAK&rft.jtitle=Biochemical%20pharmacology&rft.au=Huang,%20Rong&rft.date=2013-09-01&rft.volume=86&rft.issue=5&rft.spage=597&rft.epage=611&rft.pages=597-611&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2013.06.024&rft_dat=%3Celsevier_pubme%3ES0006295213004115%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-c7ff63cdf2ded16ede24f52a0bc451f936602241eb3b4759215c5d985c43691c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23830822&rfr_iscdi=true |